BMY
Bristol-Myers Squibb Company
$61.68
+4.84% 2026-10-20
Health CareS&P 500
BMYSPY
1W
+8.8%
1M
-1.2%
3M
+2.3%
6M
+6.1%
YTD
+19.4%
1Y
+47.8%
Live chart
Loading live chart…
Grades vs sector
Momentum73rd pct in sectorB+
Momentum
73rd pct in sector
12-1 return: +40.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth33rd pct in sectorC-
Growth
33rd pct in sector
Revenue growth (YoY): +5.7%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value89th pct in sectorA
Value
89th pct in sector
Forward E/P: 11.1% · EBITDA/EV: 12.1%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability86th pct in sectorA-
Profitability
86th pct in sector
Profit margin: +18.9% · Return on equity: +46.6%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15rank 53 of 499 · 12-1 momentum % 55.2
Momentum Blendnot in the current book
New Highs Growthrank 32 of 589 · 12-1 momentum % 58.6
Conviction 20not in the current book
News
More newsAmgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Nasdaq · 12h ago
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
BioPharma Dive · Oct 07
Key stats
Market cap$126.0B
P/E (trailing)13.6
P/E (forward)9.3
52-week range42.52 – 68.64
Revenue growth (YoY, latest qtr)+5.7%
Dividend yield4.09%
Analyst consensusBuy (24)
Mean price target$65.42 (+6%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Looks undervalued
Model read-out from the numbers below, not advice. Score +4 (DCF counts double).
▲DCF (base case)above the price by 20%
▲Forward P/E vs sector9.3x vs median 17.6x
▲Piotroski F-score7/9
•Analyst target+6% (24 analysts)
Discounted cash flow
Bear
$41
-33%
growth -1% · disc. 10.2% · term. 2.0%
Base
$74
+20%
growth 4% · disc. 9.2% · term. 2.5%
Bull
$119
+93%
growth 7% · disc. 8.2% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 1% a year for 10 years.
Implied
+1%/yr
FCF, last 3 yrs
+2%/yr
FCF, last 5 yrs
-1%/yr
Revenue, last 3 yrs
+1%/yr
Revenue, last 5 yrs
+3%/yr
Same inputs as the DCF above: trailing free cash flow 11.4B, 9.2% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.18 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 9th pct
13.6×cheaper
Forward P/E
cheaper
sector median 17.6× · 12th pct
9.3×cheaper
EV / EBITDA
sector median 15.8×
–Price / sales
cheaper
sector median 3.1× · 42nd pct
2.6×cheaper
Price / book
pricier
sector median 3.5× · 71st pct
5.6×pricier
FCF yield
cheaper
sector median 4.1% · 87th pct
9.1%cheaper
Forward EPS $6.62 vs trailing $4.54 (+46% expected growth). Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$1.3B
as of 2018-12-31
vs a year ago
–
YoY
× TTM revenue
0.03×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
62.5%
Operating margin
–
FCF margin
23.3%
Net margin
18.9%
Return on equity
41.6%
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
1.5×
Interest cover
–
Cash conversion (OCF/NI)
1.4×
Piotroski F-score 7/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved
Analysts
Mean target
$65
+6%
Analysts
24
Buy
Range
$41–$82
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $48.2B | $7.1B | $12.8B |
| 2024 | $48.3B | $-8.9B | $13.9B |
| 2023 | $45.0B | $8.0B | $12.7B |
| 2022 | $46.2B | $6.3B | $11.9B |
| 2021 | $46.4B | $7.0B | $15.2B |
| 2020 | $42.5B | $-9.0B | $13.3B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +1.4%.
Earnings
Next report: 2026-10-29 · before open · EPS est 1.28
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | 1.60 | 2.04 | +27.7% |
| 2026-04-30 | 1.42 | 1.58 | +11.2% |
| 2026-02-05 | 1.20 | 1.26 | +4.6% |
| 2025-10-30 | 1.52 | 1.63 | +7.5% |
| 2025-07-31 | 1.10 | 1.46 | +32.6% |
| 2025-04-24 | 1.50 | 1.80 | +19.9% |
| 2025-02-06 | 1.47 | 1.67 | +13.8% |
| 2024-10-31 | 1.50 | 1.80 | +20.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $13.0B | +5.7% |
| 2026-03-31 | $11.5B | – |
| 2025-12-31 | $12.5B | – |
| 2025-09-30 | $12.2B | – |
| 2025-06-30 | $12.3B | – |
Analyst actions
Wells Fargo
PT $60
2026-10-13 · main
Equal-Weight → Equal-WeightPT $60
Cantor Fitzgerald
PT $53
2026-10-08 · main
Neutral → NeutralPT $53
Morgan Stanley
PT $41
2026-10-07 · main
Underweight → UnderweightPT $41
Leerink Partners
PT $59
2026-10-05 · down
Outperform → Market PerformPT $59
Piper Sandler
PT $82
2026-09-16 · reit
Overweight → OverweightPT $82
HSBC
PT $65
2026-09-10 · main
Hold → HoldPT $65
Recent dividends
2026-10-02: $0.630 · 2026-07-02: $0.630 · 2026-04-02: $0.630 · 2026-01-02: $0.630 · 2025-10-03: $0.620 · 2025-07-03: $0.620 · 2025-04-04: $0.620 · 2025-01-03: $0.620
Stats refreshed 2026-10-21 01:32:09 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.